IntroductionGait disorders and gait-related cognitive tests were recently linked to future Alzheimer’s Disease (AD) dementia diagnosis in amnestic Mild Cognitive Impairment (aMCI). This study aimed to evaluate the predictive power of gait disorders and gait-related neuropsychological performances for future AD diagnosis in aMCI through machine learning (ML).MethodsA sample of 253 aMCI (stable, converter) individuals were included. We explored the predictive accuracy of four predictors (gait profile plus MMSE, DSST, and TMT-B) previously identified as critical for the conversion from aMCI to AD within a 36-month follow-up. Supervised ML algorithms (Support Vector Machine [SVM], Logistic Regression, and k-Nearest Neighbors) were trained on 70...
PURPOSE: The purpose of this study was to automatically identify gait patterns of geriatric patients...
Combining gait and clinical variables could increase the accuracy of identifying cognitive impairmen...
BackgroundPredicting clinical course of cognitive decline can boost clinical trials' power and impro...
Early detection of Alzheimer’s Disease and Related Disorders (ADRD) has been a focus of research wit...
BackgroundPrevious studies mainly focused on risk factors in patients with mild cognitive impairment...
International audienceWe performed a systematic review of studies focusing on the automatic predicti...
The use of wearable devices to study gait and postural control is a growing field on neurodegenerati...
One of the current challenges in the field of Alzheimer's disease (AD) is to identify patients with ...
The concept of Mild Cognitive Impairment (MCI) is used to describe the early stages of Alzheimer’s d...
Dementia, including Alzheimer’s Disease (AD), is a complex condition, and early detection remains a ...
Background: Despite the increasing availability in brain health related data, clinically translatabl...
Alzheimer\u27s Disease (AD) is a neurodegenerative disease that causes complications with thinking c...
Background: Available therapies for Alzheimer's disease (AD) can only alleviate and delay the advanc...
Mild cognitive impairment (MCI) has 10%–20% prevalence in the population above the age of 65, and a ...
Research Doctorate - Doctor of Philosophy (PhD)Alzheimer’s disease (AD) is the most common cause of ...
PURPOSE: The purpose of this study was to automatically identify gait patterns of geriatric patients...
Combining gait and clinical variables could increase the accuracy of identifying cognitive impairmen...
BackgroundPredicting clinical course of cognitive decline can boost clinical trials' power and impro...
Early detection of Alzheimer’s Disease and Related Disorders (ADRD) has been a focus of research wit...
BackgroundPrevious studies mainly focused on risk factors in patients with mild cognitive impairment...
International audienceWe performed a systematic review of studies focusing on the automatic predicti...
The use of wearable devices to study gait and postural control is a growing field on neurodegenerati...
One of the current challenges in the field of Alzheimer's disease (AD) is to identify patients with ...
The concept of Mild Cognitive Impairment (MCI) is used to describe the early stages of Alzheimer’s d...
Dementia, including Alzheimer’s Disease (AD), is a complex condition, and early detection remains a ...
Background: Despite the increasing availability in brain health related data, clinically translatabl...
Alzheimer\u27s Disease (AD) is a neurodegenerative disease that causes complications with thinking c...
Background: Available therapies for Alzheimer's disease (AD) can only alleviate and delay the advanc...
Mild cognitive impairment (MCI) has 10%–20% prevalence in the population above the age of 65, and a ...
Research Doctorate - Doctor of Philosophy (PhD)Alzheimer’s disease (AD) is the most common cause of ...
PURPOSE: The purpose of this study was to automatically identify gait patterns of geriatric patients...
Combining gait and clinical variables could increase the accuracy of identifying cognitive impairmen...
BackgroundPredicting clinical course of cognitive decline can boost clinical trials' power and impro...